Login
$BCLI
$1.05 -$0.02 (1.87%) Close

Company Executives

Officer Age In this role Joined 2024 pay Source
Chaim Lebovits
Chief Executive Officer
54 Since 2015
11 years
2007 $750,303
Peter Joe Pitts
Executive Chairman
Title from the Form 4 dated Jul 24, 2026
Not stated Not stated Not stated Not reported
Uri Yablonka Also a director
Executive Vice President, Chief Business Officer, Secretary and Director
48 Not stated 2014 $266,138
Alla Patlis
See Remarks
Title from the Form 4 dated Feb 26, 2026
38 Not stated 2012 Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
4 of 4
stated in the proxy; 3 not stated
Average tenure
7.3 years
from year joined
CEO also chairs the board
No
Jacob Frenkel
Director Age On board Independent Committees Other public boards Pay Source
Jacob Frenkel
82 2020
5 years
Not stated None stated None stated Not stated
Uri Yablonka
48 2014
11 years
Not stated None stated None stated Not stated
Irit Arbel
65 2004
21 years
Independent
Audit Committee
None stated Not stated
Menghisteab Bairu
64 2021
4 years
Independent
Audit Committee
None stated Not stated
Nir Naor
50 2023
2 years
Independent None stated None stated Not stated
Anthony Polverino
62 2018
7 years
Independent None stated None stated Not stated
Stacy Lindborg
54 2024
1 year
Not stated None stated Imunon, Inc. Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed May 16, 2025
Ramot
Amount not stated

Research and License Agreement with Ramot, the technology transfer group within Tel Aviv University, under which the Israeli Subsidiary holds rights to the Ramot IP and pays royalties.

Professor Offen
Amount not stated

Consulting agreement between the Israeli Subsidiary and Professor Offen of Tel Aviv University, granting the Israeli Subsidiary rights to work product; terminated January 18, 2018.

With Israeli Subsidiary Open in proxy
ACCBT
a company under the control of Mr. Chaim Lebovits, our President and Chief Executive Officer
Approximately $5.0 million

Subscription agreement and related registration rights and warrants under which the Company sold ACCBT 128,031 shares of Common Stock and warrants to purchase 134,444 shares, with ACCBT holding board appointment, preemptive and consent rights.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support